Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group study

C. L. Sexauer, A. Khan, P. C. Burger, J. P. Krischer, J. van Eys, T. Vats, A. H. Ragab

Research output: Contribution to journalArticle

Abstract

Forty-six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m2/day, x 2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) scan, were demonstrated in 4 of 10 patients with medulloblastoma and 3 of 15 patients with ependymoma. No activity was documented in astrocytic tumors. Dose limiting major toxicities were renal and auditory. It is recommended that the new analogues of cisplatin with less toxicity be studied in these tumors.

Original languageEnglish (US)
Pages (from-to)1497-1501
Number of pages5
JournalCancer
Volume56
Issue number7
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Brain Neoplasms
Cisplatin
Pediatrics
Ependymoma
Medulloblastoma
Drug-Related Side Effects and Adverse Reactions
Neoplasms
Tomography
Kidney
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group study. / Sexauer, C. L.; Khan, A.; Burger, P. C.; Krischer, J. P.; van Eys, J.; Vats, T.; Ragab, A. H.

In: Cancer, Vol. 56, No. 7, 1985, p. 1497-1501.

Research output: Contribution to journalArticle

Sexauer, C. L. ; Khan, A. ; Burger, P. C. ; Krischer, J. P. ; van Eys, J. ; Vats, T. ; Ragab, A. H. / Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group study. In: Cancer. 1985 ; Vol. 56, No. 7. pp. 1497-1501.
@article{fed1fb685e5f440aaeb387495c6dbbc3,
title = "Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group study",
abstract = "Forty-six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m2/day, x 2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) scan, were demonstrated in 4 of 10 patients with medulloblastoma and 3 of 15 patients with ependymoma. No activity was documented in astrocytic tumors. Dose limiting major toxicities were renal and auditory. It is recommended that the new analogues of cisplatin with less toxicity be studied in these tumors.",
author = "Sexauer, {C. L.} and A. Khan and Burger, {P. C.} and Krischer, {J. P.} and {van Eys}, J. and T. Vats and Ragab, {A. H.}",
year = "1985",
doi = "10.1002/1097-0142(19851001)56:7<1497::AID-CNCR2820560703>3.0.CO;2-7",
language = "English (US)",
volume = "56",
pages = "1497--1501",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group study

AU - Sexauer, C. L.

AU - Khan, A.

AU - Burger, P. C.

AU - Krischer, J. P.

AU - van Eys, J.

AU - Vats, T.

AU - Ragab, A. H.

PY - 1985

Y1 - 1985

N2 - Forty-six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m2/day, x 2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) scan, were demonstrated in 4 of 10 patients with medulloblastoma and 3 of 15 patients with ependymoma. No activity was documented in astrocytic tumors. Dose limiting major toxicities were renal and auditory. It is recommended that the new analogues of cisplatin with less toxicity be studied in these tumors.

AB - Forty-six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m2/day, x 2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) scan, were demonstrated in 4 of 10 patients with medulloblastoma and 3 of 15 patients with ependymoma. No activity was documented in astrocytic tumors. Dose limiting major toxicities were renal and auditory. It is recommended that the new analogues of cisplatin with less toxicity be studied in these tumors.

UR - http://www.scopus.com/inward/record.url?scp=0021926013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021926013&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19851001)56:7<1497::AID-CNCR2820560703>3.0.CO;2-7

DO - 10.1002/1097-0142(19851001)56:7<1497::AID-CNCR2820560703>3.0.CO;2-7

M3 - Article

C2 - 4040799

AN - SCOPUS:0021926013

VL - 56

SP - 1497

EP - 1501

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -